N‐Terminal Modification of Gly‐His‐Tagged Proteins with Azidogluconolactone

Site‐specific protein modifications are vital for biopharmaceutical drug development. Gluconoylation is a non‐enzymatic, post‐translational modification of N‐terminal HisTags. We report high‐yield, site‐selective in vitro α‐aminoacylation of peptides, glycoproteins, antibodies, and virus‐like partic...

Full description

Saved in:
Bibliographic Details
Published in:Chembiochem : a European journal of chemical biology Vol. 22; no. 22; pp. 3199 - 3207
Main Authors: Brune, Karl D., Liekniņa, Ilva, Sutov, Grigorij, Morris, Alexander R., Jovicevic, Dejana, Kalniņš, Gints, Kazāks, Andris, Kluga, Rihards, Kastaljana, Sabine, Zajakina, Anna, Jansons, Juris, Skrastiņa, Dace, Spunde, Karīna, Cohen, Alexander A., Bjorkman, Pamela J., Morris, Howard R., Suna, Edgars, Tārs, Kaspars
Format: Journal Article
Language:English
Published: Weinheim Wiley Subscription Services, Inc 16.11.2021
Subjects:
ISSN:1439-4227, 1439-7633, 1439-7633
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Site‐specific protein modifications are vital for biopharmaceutical drug development. Gluconoylation is a non‐enzymatic, post‐translational modification of N‐terminal HisTags. We report high‐yield, site‐selective in vitro α‐aminoacylation of peptides, glycoproteins, antibodies, and virus‐like particles (VLPs) with azidogluconolactone at pH 7.5 in 1 h. Conjugates slowly hydrolyse, but diol‐masking with borate esters inhibits reversibility. In an example, we multimerise azidogluconoylated SARS‐CoV‐2 receptor‐binding domain (RBD) onto VLPs via click‐chemistry, to give a COVID‐19 vaccine. Compared to yeast antigen, HEK‐derived RBD was immunologically superior, likely due to observed differences in glycosylation. We show the benefits of ordered over randomly oriented multimeric antigen display, by demonstrating single‐shot seroconversion and best virus‐neutralizing antibodies. Azidogluconoylation is simple, fast and robust chemistry, and should accelerate research and development. Site‐selective α‐amino acylation of proteins with N‐terminal Gly‐HisTags using 6‐azido‐6‐deoxy‐glucono‐1,5‐lactone (6AGDL) is reported. To demonstrate the usefulness of this reaction, we multimerise the SARS‐CoV‐2 receptor‐binding domain (RBD) protein antigen onto virus‐like particles (VLPs) via strain‐promoted alkyne‐azide cycloaddition (SPAAC). The resulting COVID‐19 vaccine candidate induces single‐shot seroconversion, and virus‐neutralizing antibodies in mice.
Bibliography:These authors contributed equally to this work.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1439-4227
1439-7633
1439-7633
DOI:10.1002/cbic.202100381